Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 29 publications
Tumor Lysis Syndrome in Acute Myeloid Leukemia Patients Treated With a Venetoclax Based Regimen.
Journal: European journal of haematology
Published: September 22, 2024
Evolving racial/ethnic disparities in AML survival in the novel therapy era.
Journal: Blood advances
Published: July 03, 2024
Characterization of the calcineurin inhibitor pain syndrome in patients undergoing allogeneic hematopoietic cell transplantation.
Journal: Leukemia & lymphoma
Published: January 24, 2024
OUTER RETINOPATHY AND MICROANGIOPATHY IN ACUTE MYELOGENOUS LEUKEMIA.
Journal: Retinal cases & brief reports
Published: October 30, 2023
One versus two sets of busulfan therapeutic drug monitoring in myeloablative allogeneic hematopoietic cell transplant.
Journal: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners
Published: August 21, 2023
Real-world effectiveness of intensive chemotherapy with 7&3 versus venetoclax and hypomethylating agent in acute myeloid leukemia.
Journal: American journal of hematology
Published: March 13, 2023
Clofarabine and Busulfan Myeloablative Conditioning in Allogeneic Hematopoietic Cell Transplantation for Patients With Active Myeloid Malignancies.
Journal: Transplantation and cellular therapy
Published: June 27, 2022
Pentosan polysulfate for the treatment of hemorrhagic cystitis after allogeneic hematopoietic cell transplant.
Journal: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners
Published: June 01, 2022
Low-Dose Total Body Irradiation Added to Fludarabine and Busulfan Reduced-Intensity Conditioning Reduces Graft Failure in Patients with Myelofibrosis.
Journal: Transplantation and cellular therapy
Published: May 04, 2022
Salvage therapy with basiliximab and etanercept for severe steroid-refractory acute graft-versus-host disease.
Journal: American journal of hematology
Published: March 30, 2022
Venetoclax in combination with hypomethylating agents or low dose cytarabine for relapsed and refractory acute myeloid leukemia.
Journal: Leukemia & lymphoma
Published: March 08, 2022
Last Updated: 09/26/2026